

Evangelos Xylinas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6912579/publications.pdf>

Version: 2024-02-01

161
papers

5,884
citations

87888

38
h-index

91884

69
g-index

186
all docs

186
docs citations

186
times ranked

5374
citing authors

#	ARTICLE	IF	CITATIONS
1	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. <i>Journal of Urology</i> , 2013, 189, 1214-1221.	0.4	291
2	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	1.9	235
3	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	1.9	211
4	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	1.9	201
5	Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. <i>British Journal of Cancer</i> , 2013, 109, 1460-1466.	6.4	192
6	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2015, 67, 74-82.	1.9	190
7	Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. <i>European Urology</i> , 2014, 65, 742-754.	1.9	159
8	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	2.8	154
9	Ureteral and Multifocal Tumours Have Worse Prognosis than Renal Pelvic Tumours in Urothelial Carcinoma of the Upper Urinary Tract Treated by Nephroureterectomy. <i>European Urology</i> , 2011, 60, 1258-1265.	1.9	147
10	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019, 10, 2977.	12.8	140
11	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	1.9	134
12	Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. <i>European Journal of Surgical Oncology</i> , 2014, 40, 121-127.	1.0	132
13	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer: An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
14	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	2.5	128
15	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	1.9	125
16	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. <i>European Urology</i> , 2014, 66, 913-919.	1.9	103
17	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	1.9	101
18	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer: an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	1.2	96

#	ARTICLE	IF	CITATIONS
19	Multifocal Carcinoma In Situ of the Upper Tract Is Associated With High Risk of Bladder Cancer Recurrence. <i>European Urology</i> , 2012, 61, 1069-1070.	1.9	94
20	Urine markers for detection and surveillance of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 222-229.	1.6	91
21	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	1.9	78
22	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	2.2	75
23	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. <i>World Journal of Urology</i> , 2017, 35, 337-353.	2.2	74
24	Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. <i>World Journal of Urology</i> , 2013, 31, 61-68.	2.2	72
25	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology's "Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	2.5	61
26	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.4	58
27	Impact of perioperative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>BJU International</i> , 2014, 113, 393-398.	2.5	54
28	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 483.e17-483.e24.	1.6	54
29	The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. <i>BJU International</i> , 2012, 110, 43-49.	2.5	53
30	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in perioperative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	2.5	53
31	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. <i>European Urology Focus</i> , 2019, 5, 681-688.	3.1	48
32	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2120-2128.	0.4	45
33	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. <i>Biomolecules</i> , 2016, 6, 37.	4.0	44
34	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. <i>BJU International</i> , 2014, 114, 56-61.	2.5	41
35	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	5.4	41
36	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	0.4	40

#	ARTICLE	IF	CITATIONS
37	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	5.4	40
38	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 5-11.	2.2	39
39	Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. <i>Urology</i> , 2013, 82, 1323-1329.	1.0	38
40	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e7-49.e14.	1.6	38
41	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	2.2	37
42	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
43	Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: Trifecta rate of achieving continence, potency and cancer control. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 99-103.	1.6	36
44	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e17-8.e24.	1.6	36
45	Prospective External Validation of a Bladder Cancer Detection Model. <i>Journal of Urology</i> , 2014, 192, 1343-1348.	0.4	35
46	Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. <i>British Journal of Cancer</i> , 2012, 107, 1826-1832.	6.4	34
47	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	1.6	33
48	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. <i>BJU International</i> , 2019, 124, 738-745.	2.5	32
49	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	1.6	31
50	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e19-e27.	1.9	31
51	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. <i>Cancer Biology and Therapy</i> , 2014, 15, 1239-1247.	3.4	30
52	Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 113-120.	1.0	29
53	Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. <i>BJU International</i> , 2016, 117, 272-279.	2.5	29
54	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	2.2	29

#	ARTICLE	IF	CITATIONS
55	The contemporary role and impact of urine-based biomarkers in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1031-1042.	1.4	29
56	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. <i>World Journal of Urology</i> , 2018, 36, 1621-1627.	2.2	29
57	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 73-79.	5.4	29
58	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.6	29
59	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. <i>World Journal of Urology</i> , 2015, 33, 1945-1950.	2.2	28
60	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	1.9	27
61	Immune checkpoint inhibition in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1357-1367.	2.2	27
62	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	1.9	27
63	Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1238-1243.	0.4	26
64	Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 31-36.	2.2	25
65	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1027-1034.	1.5	25
66	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 625-630.	1.6	25
67	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. <i>Journal of Urology</i> , 2015, 194, 1456-1462.	0.4	25
68	Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2017, 35, 229-235.	2.2	25
69	Is Robot Assistance Affecting Operating Room Time Compared with Pure Retroperitoneal Laparoscopic Radical Prostatectomy?. <i>Journal of Endourology</i> , 2009, 23, 939-943.	2.1	24
70	Intrafascial Nerve-Sparing Radical Prostatectomy with a Laparoscopic Robot-Assisted Extraperitoneal Approach: Early Oncological and Functional Results. <i>Journal of Endourology</i> , 2010, 24, 577-582.	2.1	24
71	Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. <i>British Journal of Cancer</i> , 2014, 111, 213-219.	6.4	24
72	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. <i>European Urology</i> , 2014, 66, 439-446.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1600-1610.	3.7	24
74	Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 9-23.	1.5	22
75	Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 769.	2.0	22
76	Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1873-1881.	2.5	21
77	Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. <i>European Urology Focus</i> , 2021, 7, 1347-1354.	3.1	21
78	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.4	19
79	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 580-593.	5.4	19
80	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018, 4, 252-259.	3.1	18
81	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. <i>European Urology Focus</i> , 2020, 6, 1226-1232.	3.1	18
82	Lymphadenectomy for Upper Tract Urothelial Carcinoma: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 1190.	2.4	17
83	Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1693-1699.	1.0	16
84	Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience. <i>Frontiers in Surgery</i> , 2018, 5, 58.	1.4	16
85	Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. <i>World Journal of Urology</i> , 2020, 39, 2545-2552.	2.2	16
86	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. <i>World Journal of Urology</i> , 2018, 36, 1775-1781.	2.2	15
87	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.6	15
88	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , 2016, 118, 243-249.	2.5	14
89	Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 65-71.	2.2	14
90	Prediction tools in non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 39-45.	1.4	14

#	ARTICLE	IF	CITATIONS
91	Active surveillance for non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 54-60.	1.4	14
92	Re: Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 113-114.	1.9	14
93	Laparoscopic Partial Nephrectomy: Is It Worth Still Performing the Retroperitoneal Route?. <i>Advances in Urology</i> , 2012, 2012, 1-5.	1.3	13
94	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1192.	2.4	13
95	The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. <i>Journal of Endourology</i> , 2020, 34, 795-804.	2.1	13
96	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , 2021, 39, 443-451.	2.2	13
97	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , 2022, 8, 491-497.	3.1	13
98	Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. <i>European Urology</i> , 2014, 66, 811-814.	1.9	12
99	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 3833-3838.	1.5	11
100	Robot-assisted extraperitoneal laparoscopic radical prostatectomy: A review of the current literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 288-293.	1.6	11
101	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	3.1	11
102	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. <i>World Journal of Urology</i> , 2020, 39, 4055-4065.	2.2	11
103	The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Urology</i> , 2020, 18, 67-71.	1.5	11
104	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 885-893.	0.4	11
105	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e21-33.e26.	1.6	10
106	Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882367.	2.0	10
107	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1786-1793.	1.4	10
108	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 76-85.	4.4	9

#	ARTICLE	IF	CITATIONS
109	Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1962.	2.4	9
110	Perioperative chemotherapy for upper tract urothelial carcinoma: show me the evidence. <i>Current Opinion in Urology</i> , 2021, 31, 66-67.	1.8	9
111	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. <i>Current Oncology</i> , 2022, 29, 687-697.	2.2	9
112	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e1-47.e8.	1.6	8
113	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.4	8
114	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e1-179.e7.	1.6	8
115	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1780-1785.	1.4	8
116	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	1.6	8
117	Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 165-172.	2.2	7
118	The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. <i>Progres En Urologie</i> , 2020, 30, 322-331.	0.8	7
119	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	1.6	7
120	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. <i>Cancers</i> , 2020, 12, 3063.	3.7	7
121	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology "Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	3.1	7
122	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. <i>European Urology Focus</i> , 2015, 1, 75-81.	3.1	6
123	Immunotherapy for metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 1-7.	1.8	6
124	Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e1-89.e5.	1.6	6
125	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.	1.6	6
126	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. <i>European Urology Open Science</i> , 2020, 22, 45-50.	0.4	6

#	ARTICLE	IF	CITATIONS
127	Assessment of the oncological outcomes of three different bacillus Calmette-Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. Arab Journal of Urology Arab Association of Urology, 2021, 19, 78-85.	1.5	6
128	Lymph Node Dissection During Radical Nephro-Ureterectomy for Upper Tract Urothelial Carcinoma: A Review. Frontiers in Surgery, 2022, 9, 852969.	1.4	6
129	Systematic review and meta-analysis on bipolar versus monopolar transurethral resection of bladder tumors. Translational Andrology and Urology, 2021, 10, 37-48.	1.4	5
130	Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvic/ureteral System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. European Urology Focus, 2021, 7, 1075-1083.	3.1	5
131	Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 535-535.	1.6	5
132	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	2.2	4
133	The need to improve TURB: a diagnostic and therapeutic fundamental first step in the disease's management. Translational Andrology and Urology, 2019, 8, 2-4.	1.4	4
134	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. Journal of Clinical Medicine, 2020, 9, 3306.	2.4	4
135	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 4345-4354.	2.2	4
136	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. Minerva Urology and Nephrology, 2021, , .	2.5	4
137	Segmental ureterectomy for upper tract urothelial carcinoma: Two procedures with different indications. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1841-1843.	1.6	3
138	Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-related Events in Patients with Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial. European Urology, 2013, 63, 1132-1133.	1.9	3
139	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e19-238.e27.	1.6	3
140	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	1.9	3
141	PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non-muscle invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, 4550-4550.	1.6	3
142	Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review. Current Opinion in Urology, 2022, 32, 54-60.	1.8	3
143	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clinical Genitourinary Cancer, 2022, 20, 227-236.	1.9	3
144	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. World Journal of Urology, 2022, 40, 1489-1496.	2.2	3

#	ARTICLE	IF	CITATIONS
145	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	1.9	3
146	Uptake of Laparoscopic Radical Nephroureterectomy in France: A 2003â€“2011 National Practice Report. <i>European Urology</i> , 2012, 62, 940-942.	1.9	2
147	Angiotensin System Inhibitors in Renal Cell Carcinomaâ€”Letter. <i>Clinical Cancer Research</i> , 2016, 22, 524-524.	7.0	2
148	Re: Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. <i>European Urology</i> , 2013, 64, 683-684.	1.9	1
149	Re: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2017, 72, 473-474.	1.9	1
150	The present and future of non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 1-1.	1.4	1
151	Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma. <i>Bladder Cancer</i> , 2022, 8, 315-327.	0.4	1
152	HBP, transplantation rÃ©nale, vessie et tumeur urothÃ©liale, OGE, neuro-urologie, incontinence de lâ€™homme et de la femme. <i>ProgrÃ©s En Urologie - FMC</i> , 2008, 18, F33-F37.	0.1	0
153	Tumeurs urothÃ©liales, incontinence, organes gÃ©nitaux externes et transplantation rÃ©nale. <i>ProgrÃ©s En Urologie - FMC</i> , 2011, 21, F32-F35.	0.1	0
154	Re: Impact of Smoking Status on Bladder Tumor Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 557-559.	0.4	0
155	Prevention of IVR: a need for investigation. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 295-296.	1.3	0
156	Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?. <i>European Urology</i> , 2019, 76, 256-257.	1.9	0
157	Tumores primarios de la uretra en el varÃ³n. <i>EMC - UrologÃ­a</i> , 2020, 52, 1-5.	0.0	0
158	Immunotherapy in genitourinary cancers: achievements and perspectives. <i>World Journal of Urology</i> , 2021, 39, 1317-1317.	2.2	0
159	Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma. , 2015, , 91-117.		0
160	Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract.. <i>Journal of Clinical Oncology</i> , 2017, 35, 358-358.	1.6	0
161	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16022-e16022.	1.6	0